Search Results

$9 million grant supports new study of utilizing semaglutide for non-alcoholic fatty liver disease.

Union Health Ministry releases updated NAFLD guidelines to improve patient care, emphasizing early detection, lifestyle changes, and holistic care strategies

Using the latest technologies—advanced 3D glass imaging of mice to characterize key scar-producing liver cells—researchers have uncovered novel candidate drug targets for NAFLD

While obesity and diabetes are well-known risk factors for fatty liver disease, the UT Southwestern researchers were able to identify a new cause of fatty liver disease absent obesity.

The FDA's approval was based on Rezdiffra's potential to create significant improvements in liver scarring in a relatively short period of time.

Promising treatment in clinical trials has double action against triglyceride and fatty acid synthesis, UTSW study shows